Pneumococcal vaccine and opsonic pneumococcal antibody

Joon-Young Song, M. Allen Moseley, Robert L. Burton, Moon H. Nahm

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Streptococcus pneumoniae is a major human pathogen responsible for the majority of bacterial pneumonia cases as well as invasive pneumococcal diseases with high mortality and morbidity. Use of conjugate vaccines targeting the pneumococcal capsule has dramatically reduced the incidence of invasive diseases, and there are active efforts to further improve the conjugate vaccines. However, in children new pneumococcal vaccines can no longer be tested with placebo-based clinical trials because effective vaccines are currently available. Thus, vaccine studies must depend on surrogate markers of vaccine efficacy. Although traditional antibody levels (e.g., ELISA) are useful as a surrogate marker of protection, they have limitations, and a bioassay measuring the capacity of antibodies to opsonize pneumococci has been developed. This opsonophagocytosis assay (OPA) replicates the in vivo mechanism of antibody protection and should therefore better reflect protection by vaccine-induced antibodies. Technical improvements of OPA have made this bioassay rapid, multiplexed, and practical for analyzing small samples including those from children. Strong correlations between ELISA and OPA have been observed in many studies of young children. However, poor correlations have been found in some important clinical situations (such as determination of protection by cross-reactive antibodies) and populations (such as elderly adults and immunodeficient patients). In these settings, OPA has become a useful supplementary measure of pneumococcal vaccine immunogenicity. Current efforts to standardize OPA will further expand its uses.

Original languageEnglish
Pages (from-to)412-425
Number of pages14
JournalJournal of Infection and Chemotherapy
Volume19
Issue number3
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Pneumococcal Vaccines
Antibodies
Conjugate Vaccines
Vaccines
Streptococcus pneumoniae
Biological Assay
Marker Vaccines
Biomarkers
Enzyme-Linked Immunosorbent Assay
Cross Protection
Bacterial Pneumonia
Capsules
Placebos
Clinical Trials
Morbidity
Mortality
Incidence
Population

Keywords

  • Immunogenicity
  • Opsonophagocytic killing assay
  • Pneumococcal vaccine
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Pneumococcal vaccine and opsonic pneumococcal antibody. / Song, Joon-Young; Moseley, M. Allen; Burton, Robert L.; Nahm, Moon H.

In: Journal of Infection and Chemotherapy, Vol. 19, No. 3, 01.01.2013, p. 412-425.

Research output: Contribution to journalReview article

Song, Joon-Young ; Moseley, M. Allen ; Burton, Robert L. ; Nahm, Moon H. / Pneumococcal vaccine and opsonic pneumococcal antibody. In: Journal of Infection and Chemotherapy. 2013 ; Vol. 19, No. 3. pp. 412-425.
@article{6934cd8980804ca99c2833710649bcfa,
title = "Pneumococcal vaccine and opsonic pneumococcal antibody",
abstract = "Streptococcus pneumoniae is a major human pathogen responsible for the majority of bacterial pneumonia cases as well as invasive pneumococcal diseases with high mortality and morbidity. Use of conjugate vaccines targeting the pneumococcal capsule has dramatically reduced the incidence of invasive diseases, and there are active efforts to further improve the conjugate vaccines. However, in children new pneumococcal vaccines can no longer be tested with placebo-based clinical trials because effective vaccines are currently available. Thus, vaccine studies must depend on surrogate markers of vaccine efficacy. Although traditional antibody levels (e.g., ELISA) are useful as a surrogate marker of protection, they have limitations, and a bioassay measuring the capacity of antibodies to opsonize pneumococci has been developed. This opsonophagocytosis assay (OPA) replicates the in vivo mechanism of antibody protection and should therefore better reflect protection by vaccine-induced antibodies. Technical improvements of OPA have made this bioassay rapid, multiplexed, and practical for analyzing small samples including those from children. Strong correlations between ELISA and OPA have been observed in many studies of young children. However, poor correlations have been found in some important clinical situations (such as determination of protection by cross-reactive antibodies) and populations (such as elderly adults and immunodeficient patients). In these settings, OPA has become a useful supplementary measure of pneumococcal vaccine immunogenicity. Current efforts to standardize OPA will further expand its uses.",
keywords = "Immunogenicity, Opsonophagocytic killing assay, Pneumococcal vaccine, Streptococcus pneumoniae",
author = "Joon-Young Song and Moseley, {M. Allen} and Burton, {Robert L.} and Nahm, {Moon H.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/s10156-013-0601-1",
language = "English",
volume = "19",
pages = "412--425",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Pneumococcal vaccine and opsonic pneumococcal antibody

AU - Song, Joon-Young

AU - Moseley, M. Allen

AU - Burton, Robert L.

AU - Nahm, Moon H.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Streptococcus pneumoniae is a major human pathogen responsible for the majority of bacterial pneumonia cases as well as invasive pneumococcal diseases with high mortality and morbidity. Use of conjugate vaccines targeting the pneumococcal capsule has dramatically reduced the incidence of invasive diseases, and there are active efforts to further improve the conjugate vaccines. However, in children new pneumococcal vaccines can no longer be tested with placebo-based clinical trials because effective vaccines are currently available. Thus, vaccine studies must depend on surrogate markers of vaccine efficacy. Although traditional antibody levels (e.g., ELISA) are useful as a surrogate marker of protection, they have limitations, and a bioassay measuring the capacity of antibodies to opsonize pneumococci has been developed. This opsonophagocytosis assay (OPA) replicates the in vivo mechanism of antibody protection and should therefore better reflect protection by vaccine-induced antibodies. Technical improvements of OPA have made this bioassay rapid, multiplexed, and practical for analyzing small samples including those from children. Strong correlations between ELISA and OPA have been observed in many studies of young children. However, poor correlations have been found in some important clinical situations (such as determination of protection by cross-reactive antibodies) and populations (such as elderly adults and immunodeficient patients). In these settings, OPA has become a useful supplementary measure of pneumococcal vaccine immunogenicity. Current efforts to standardize OPA will further expand its uses.

AB - Streptococcus pneumoniae is a major human pathogen responsible for the majority of bacterial pneumonia cases as well as invasive pneumococcal diseases with high mortality and morbidity. Use of conjugate vaccines targeting the pneumococcal capsule has dramatically reduced the incidence of invasive diseases, and there are active efforts to further improve the conjugate vaccines. However, in children new pneumococcal vaccines can no longer be tested with placebo-based clinical trials because effective vaccines are currently available. Thus, vaccine studies must depend on surrogate markers of vaccine efficacy. Although traditional antibody levels (e.g., ELISA) are useful as a surrogate marker of protection, they have limitations, and a bioassay measuring the capacity of antibodies to opsonize pneumococci has been developed. This opsonophagocytosis assay (OPA) replicates the in vivo mechanism of antibody protection and should therefore better reflect protection by vaccine-induced antibodies. Technical improvements of OPA have made this bioassay rapid, multiplexed, and practical for analyzing small samples including those from children. Strong correlations between ELISA and OPA have been observed in many studies of young children. However, poor correlations have been found in some important clinical situations (such as determination of protection by cross-reactive antibodies) and populations (such as elderly adults and immunodeficient patients). In these settings, OPA has become a useful supplementary measure of pneumococcal vaccine immunogenicity. Current efforts to standardize OPA will further expand its uses.

KW - Immunogenicity

KW - Opsonophagocytic killing assay

KW - Pneumococcal vaccine

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84879227463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879227463&partnerID=8YFLogxK

U2 - 10.1007/s10156-013-0601-1

DO - 10.1007/s10156-013-0601-1

M3 - Review article

VL - 19

SP - 412

EP - 425

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 3

ER -